The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

CONCLUSIONS: In this large safety analysis, the risk of malignancy was low for up to five years of secukinumab treatment. These data support the long-term us of secukinumab in these indications.PMID:33829482 | DOI:10.1111/bjd.20136

Source: The British Journal of Dermatology - April 8, 2021 Category: Dermatology Authors: M Lebwohl A Deodhar C E M Griffiths M A Menter D Poddubnyy W Bao V Jehl K Marfo P Primatesta A Shete V Trivedi P J Mease Source Type: research